Accéder au contenu
Merck

Echinomycin biosynthesis.

Current opinion in chemical biology (2013-07-17)
Michio Sato, Takehito Nakazawa, Yuta Tsunematsu, Kinya Hotta, Kenji Watanabe
RÉSUMÉ

Echinomycin is an antitumor antibiotic secondary metabolite isolated from streptomycetes, whose core structure is biosynthesized by nonribosomal peptide synthetase (NRPS). The echinomycin biosynthetic pathway was successfully reconstituted in Escherichia coli. NRPS often contains a thioesterase domain at its C terminus for cyclorelease of the elongating peptide chain. Those thioesterase domains were shown to exhibit significant substrate tolerance. More recently, an oxidoreductase Ecm17, which forms the disulfide bridge in triostin A, was characterized. Surprisingly, an unrelated disulfide-forming enzyme GliT for gliotoxin biosynthesis was also able to catalyze the same reaction, providing another example of broad substrate specificity in secondary metabolite biosynthetic enzymes. Those promiscuous catalysts can be a valuable tool in generating diversity in natural products analogs we can produce heterologously.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Echinomycin, ≥98% (HPLC)